About Tesamorelin

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). Originally developed and approved for the reduction of visceral adipose tissue in HIV-associated lipodystrophy, it has since been studied extensively as a GH-secretagogue — meaning it doesn’t supply GH directly but stimulates the pituitary to release the body’s own.

Because it works through the natural GH axis, Tesamorelin produces a physiological GH pulse rather than the sustained high serum levels of exogenous HGH. The downstream IGF-1 increase is significant, but the feedback regulation of the GH axis remains largely intact. That distinction matters for cycle planning and safety profile relative to direct HGH research.

Dosing observed in research literature

Application	Dose	Frequency	Notes
Standard research dose	1 mg / day	Once daily, evening	Evening dosing mimics natural GH pulse during sleep
Original clinical dose	2 mg / day	Once daily, evening	HIV-lipodystrophy trial dose
Low-range research	0.5 mg / day	Once daily	For sensitivity assessment in early protocols

Standard research cycles run 8–16 weeks on, followed by 4–8 weeks off. The off-period allows the GHRH receptor system to reset; continuous use beyond 16 weeks shows diminishing IGF-1 elevation in some published data.

Typical reconstitution protocols

Tesamorelin ships as a 2 mg, 5 mg, or 10 mg lyophilised vial. Recommended reconstitutions for a typical 1 mg dose:

Vial size	Recommended BAC water	Concentration	1 mg draw	2 mg draw
2 mg	1 mL	2 mg / mL	50 units (U-100)	n/a — full vial
2 mg	2 mL	1 mg / mL	100 units (full barrel)	n/a
5 mg	2 mL	2.5 mg / mL	40 units	80 units
5 mg	2.5 mL	2 mg / mL	50 units	100 units
10 mg	2 mL	5 mg / mL	20 units	40 units

For a 5 mg vial, 2.5 mL of BAC water gives a clean 50-unit draw for a standard 1 mg dose. For a 10 mg vial, 2 mL keeps the draw at a comfortable 20 units.

Half-life and frequency

Tesamorelin has a very short plasma half-life of ~23–26 minutes. That looks like it would demand multiple daily doses, but it doesn’t — the GH pulse it triggers in the pituitary lasts hours, and the downstream IGF-1 elevation persists for 12–24 hours. Once-daily dosing is therefore standard and effective.

Evening administration is preferred in most research protocols because it aligns with the body’s natural nighttime GH peak — the additional Tesamorelin-induced pulse stacks with endogenous secretion rather than competing with it.

Storage and shelf life

Lyophilised: store at 2–8°C refrigerated. Reconstituted: stable refrigerated for 14–21 days — slightly shorter than the typical 28-day BAC water window because of Tesamorelin’s protein structure. Don’t freeze a reconstituted vial.

Frequently asked questions

What’s the difference between Tesamorelin and CJC-1295?

Both are GHRH analogues, but Tesamorelin is the closer to human GHRH structurally and is the only one with formal clinical approval (for HIV lipodystrophy). CJC-1295 (especially with DAC) has a much longer half-life and a stronger sustained-release profile. Tesamorelin produces more physiological pulses; CJC-1295 produces a more sustained baseline elevation.

How long until I see effects in research?

IGF-1 levels in research typically begin to elevate within 1–2 weeks of starting Tesamorelin. Visceral fat reduction — the most-studied endpoint — generally requires 12+ weeks for measurable change in trial data.

Can Tesamorelin be stacked with Ipamorelin?

This is a common stacking protocol in research — GHRH (Tesamorelin) and GHRP (Ipamorelin) act on different pituitary pathways and produce synergistic GH release. Typical combined research dose: Tesamorelin 1 mg + Ipamorelin 200–300 mcg, both in the evening.

Does Tesamorelin affect blood glucose?

Yes — elevated GH and IGF-1 transiently increase insulin resistance. In clinical trials a small percentage of subjects showed reduced glucose tolerance. Research protocols monitor fasting glucose and HbA1c, especially in extended cycles.

Why is Tesamorelin so much more expensive than other GHRH peptides?

Tesamorelin is the only GHRH analogue with formal pharmaceutical approval, manufacturing standards, and patent protection lineage. Research suppliers produce comparable molecules but the synthesis complexity (longer peptide chain, multiple modifications) keeps the unit cost above CJC-1295 and similar GHRH peptides.

What injection site is used for Tesamorelin?

Subcutaneous abdominal injection is the standard. Site rotation around the abdomen reduces the small risk of local irritation across an 8–16 week cycle.

Related compounds

Tesamorelin sits in the growth and performance category. Related: Ipamorelin + CJC-1295 (alternative GH-releasing stack), IGF-1 LR3 (downstream of Tesamorelin’s GH pulse), HGH (direct GH versus the secretagogue approach). Full category: Growth & Performance Peptides.